Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6–17 Years

The attenuated recombinant Vibrio cholerae O1 vaccine strain CVD 103-HgR, redeveloped as PXVX0200, elicits a rapid serum vibriocidal antibody (SVA) response and protects against cholera-induced diarrhea in adult volunteer challenge trials but has not been studied in children in developed countries....

Descripción completa

Detalles Bibliográficos
Autores principales: McCarty, James M., Gierman, Emma C., Bedell, Lisa, Lock, Michael D., Bennett, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947768/
https://www.ncbi.nlm.nih.gov/pubmed/31769402
http://dx.doi.org/10.4269/ajtmh.19-0241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947768/
https://www.ncbi.nlm.nih.gov/pubmed/31769402
http://dx.doi.org/10.4269/ajtmh.19-0241

Ejemplares similares